LECT2 and neoplasm: Two weeks after the initiation of therapy, treatment of α-PD-L1 antibody resulted in significant tumor inhibition in Lect2+/+ EOC (P < 0.05) in contrast to the tumor development in Lect2−/− EOC (P < 0.05), demonstrating a significant difference in early tumor response to PD-L1blockade between Lect2+/+ EOC and Lect2−/− EOC (P < 0.01; Fig. 8E).